

## **Mymetics announces change of Directors and management**

- Ronald Kempers appointed President and CEO
- Departure of Dr. Christopher S. Henney and Grant Pickering

**Epalinges, Switzerland, 27 November 2012** – Mymetics Corporation, a pioneer in the development of vaccines that use the human mucosal system, the body's first line of defense, to prevent transmission of infectious diseases, announced today the appointment of Ronald Kempers, currently CFO and COO, as President and CEO of Mymetics Corporation effective November 19, 2012. He replaces Dr. Christopher S. Henney and Grant Pickering who had been respectively appointed on March 22, 2012 as director and Chairman of the Board of Directors and as a director and President and Chief Executive Officer to pursue new strategic directions, including the potential change of Mymetics' location from Switzerland to the United States.

Mymetics will maintain its principal place of business in Switzerland as it explores a number of strategic opportunities for its HIV, RSV and other vaccine candidates under development. Mymetics will provide an update in due time.

### **About Mymetics**

Mymetics Corporation is a Swiss-based biotechnology company registered in the US (OTC BB: MYMX) developing next-generation preventative vaccines for infectious diseases. Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins with the ability to be combined with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which for some pathogens may be essential for the development of an effective prophylactic vaccine. Mymetics currently has five vaccines in its pipeline: Respiratory Syncytial Virus, Influenza, HIV-1/AIDS, Malaria and Herpes Simplex Virus. The company's influenza, HIV-1 and malaria vaccines have completed Phase I clinical trials in healthy human volunteers, while the RSV and HSV vaccine candidates are in preclinical development. For further information, please visit [www.mymetics.com](http://www.mymetics.com).

### **Contact**

Ronald Kempers  
President and CEO  
Mymetics Corporation  
Tel: +41 21 653 4884

### **Media United States**

Michelle Linn  
Linnden Communications  
Tel: 508 362 3087  
E-mail : [linnmich@comcast.net](mailto:linnmich@comcast.net)

Press release

**Media Europe**

Christophe Lamps

Senior Partner

Dynamics Group

Mobile: + 41 79 476 26 87

E-mail: [cla@dynamicsgroup.ch](mailto:cla@dynamicsgroup.ch)

**Forward-looking statements**

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.